168 related articles for article (PubMed ID: 19263612)
1. [Treatment for recurrent ovarian cancer].
Hasegawa K; Torii H; Ooe S; Udagawa Y
Gan To Kagaku Ryoho; 2009 Feb; 36(2):230-6. PubMed ID: 19263612
[No Abstract] [Full Text] [Related]
2. [Second-line treatment using novel chemotherapeutic and biologic agents].
Sugiyama T
Gan To Kagaku Ryoho; 2009 May; 36(5):730-5. PubMed ID: 19461172
[TBL] [Abstract][Full Text] [Related]
3. Positioning pemetrexed in the treatment of ovarian cancer.
Ledermann JA; Stebbing J
Eur J Cancer; 2009 May; 45(8):1330-2. PubMed ID: 19264477
[No Abstract] [Full Text] [Related]
4. Optimizing management of recurrent epithelial ovarian cancer: a critical need for evidence-based data.
Markman M
Oncology; 2006; 71(5-6):309-11. PubMed ID: 17873498
[No Abstract] [Full Text] [Related]
5. [Initial treatment for ovarian cancer].
Suzuki M; Fujiwara H; Takei Y
Gan To Kagaku Ryoho; 2009 Feb; 36(2):224-9. PubMed ID: 19263611
[No Abstract] [Full Text] [Related]
6. [Advanced ovarian cancer: a need for redefining therapeutic objectives and strategy].
Bugat R; Guastalla JP; Misset JL
Bull Cancer; 2005 Nov; 92(11):1003-6. PubMed ID: 16316835
[No Abstract] [Full Text] [Related]
7. Predicting ovarian tumor response.
Foubister V
Drug Discov Today; 2005 Mar; 10(6):380-1. PubMed ID: 15808813
[No Abstract] [Full Text] [Related]
8. Pros and cons for systemic therapy in recurrent ovarian cancer.
Oskay-Ozcelik G; Sehouli J
Anticancer Res; 2009 Jul; 29(7):2831-6. PubMed ID: 19596970
[TBL] [Abstract][Full Text] [Related]
9. Another example of the highly variable clinical course of recurrent/resistant/persistent ovarian cancer.
Markman M
Cancer Invest; 2006 Feb; 24(1):109. PubMed ID: 16467001
[No Abstract] [Full Text] [Related]
10. Ovarian cancer and its treatment.
Grönroos M; Laurén P; Lehto J; Rauramo L
Ann Chir Gynaecol Fenn; 1969; 58(2):83-9. PubMed ID: 5363960
[No Abstract] [Full Text] [Related]
11. [Clinical aspects and results of treatment of malignant ovarian tumors].
Carol W; Kupfer G
Munch Med Wochenschr; 1965 Nov; 107(47):2348-53. PubMed ID: 5899202
[No Abstract] [Full Text] [Related]
12. Drug resistance in ovarian cancer: biomarkers and treatments Highlights from the DROC meeting held in Modena (Italy) on the 19th and 20th of February 2009. Scientific topics discussed at the meeting are reported in the present issue.
Costi MP; Zeillinger R
Gynecol Oncol; 2010 May; 117(2):149-51. PubMed ID: 20363442
[No Abstract] [Full Text] [Related]
13. [Time interval between ovarian cancer surgery and chemotherapy--secondary publication?].
Larsen EP; Blaakaer J
Ugeskr Laeger; 2009 Nov; 171(45):3265-8. PubMed ID: 19916194
[TBL] [Abstract][Full Text] [Related]
14. [High dose chemotherapy in ovarian and breast adenocarcinoma with poor prognosis].
Lotz JP; Gligorov J; Selle F; Lefevre G; Pautier P; Lhommé C
Gynecol Obstet Fertil; 2000 Sep; 28(9):620-31. PubMed ID: 11075500
[No Abstract] [Full Text] [Related]
15. Chemosensitivity and chemoresistance testing.
Markman M
J Clin Oncol; 2005 Oct; 23(29):7363-4. PubMed ID: 16210675
[No Abstract] [Full Text] [Related]
16. Management of recurrent ovarian carcinoma: current status and future directions.
Martin LP; Schilder RJ
Semin Oncol; 2009 Apr; 36(2):112-25. PubMed ID: 19332246
[TBL] [Abstract][Full Text] [Related]
17. Advanced ovarian cancer: a clinical update on first-line treatment, recurrent disease, and new agents.
Ozols RF
J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S60-73. PubMed ID: 19780247
[TBL] [Abstract][Full Text] [Related]
18. Ovarian cancer: current management.
Tyler H; Kardinal CG
Mo Med; 1981 Jan; 78(1):13-6. PubMed ID: 7219403
[No Abstract] [Full Text] [Related]
19. Aggressive surgery and ovarian cancer.
Chi DS; Barakat RR
J Clin Oncol; 2006 May; 24(15):2395-6; author reply 2396-7. PubMed ID: 16710043
[No Abstract] [Full Text] [Related]
20. [Chemotherapy of gynecologic malignancies].
Slot E
Cesk Gynekol; 1969 Dec; 34(10):606-8. PubMed ID: 5360770
[No Abstract] [Full Text] [Related]
[Next] [New Search]
